Literature DB >> 32152526

Deciphering colistin heteroresistance in Acinetobacter baumannii clinical isolates from Wenzhou, China.

Lijiang Chen1, Jie Lin1, Hong Lu2, Xiucai Zhang1, Chong Wang1, Haiyang Liu1, Xiaoxiao Zhang1, Jiahui Li1, Jianming Cao3, Tieli Zhou4.   

Abstract

This study aimed to investigate the characteristics and mechanisms responsible for heteroresistance to colistin in Acinetobactor baumannii clinical isolates from a Chinese teaching hospital. Five hundred and seventy-six nonduplicate A. baumannii clinical isolates isolated from 2014 to 2015 were tested. Colistin heteroresistance was determined using population analysis profiles (PAPs). Susceptibility testing was conducted using the broth microdilution method (BMD). The ability to form biofilm formation was determined using 96-well flat bottom microtiter plates. Time-kill assays were also conducted. PCR and sequencing were used to detect the presence of resistant genes. Expression levels of efflux pump genes were determined by qRT-PCR. LPS analysis was conducted by SDS-PAGE. Lipid A characteristic were determined via MALDI-TOF MS. Nine colistin heteroresistant A. baumannii clinical isolates which were selected by PAPs, exhibited multidrug-resistant phenotypes. The microplate biofilm assay revealed that colistin heteroresistant A. baumannii clinical isolates had weaker biofilm formation capacity than A. baumannii ATCC19606. Colistin-heteroresistant A. baumannii isolates exhibited regrowth after 12 h at 0.5 × MIC, 1 × MIC, and 2 × MIC. The results of PCR and sequencing revealed mutations of lpxACD in some colistin heteroresistant A. baumannii isolates. qRT-PCR also showed that the expressions of efflux pump genes were upregulated in some of the heteroresistant isolates. Our study was the first report of colistin heteroresistant A. baumannii clinical isolates in China. The transition of colistin heteroresistance to resistance should be of concern in future clinical surveillance.

Entities:  

Year:  2020        PMID: 32152526     DOI: 10.1038/s41429-020-0289-2

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  4 in total

1.  Resistance and Heteroresistance to Colistin in Escherichia coli Isolates from Wenzhou, China.

Authors:  Wenli Liao; Jie Lin; Huaiyu Jia; Cui Zhou; Ying Zhang; Yishuai Lin; Jianzhong Ye; Jianming Cao; Tieli Zhou
Journal:  Infect Drug Resist       Date:  2020-10-09       Impact factor: 4.003

2.  Heteroresistance Is Associated With in vitro Regrowth During Colistin Treatment in Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Yifan Wang; Xinqian Ma; Lili Zhao; Yukun He; Wenyi Yu; Shining Fu; Wentao Ni; Zhancheng Gao
Journal:  Front Microbiol       Date:  2022-04-07       Impact factor: 6.064

3.  Naringenin restores colistin activation against colistin-resistant gram-negative bacteria in vitro and in vivo.

Authors:  Mengxin Xu; Zhuocheng Yao; Yining Zhao; Shiyi Shi; Yao Sun; Luozhu Feng; Cui Zhou; Xiaodong Zhang; Jianming Cao; Tieli Zhou
Journal:  Front Microbiol       Date:  2022-08-03       Impact factor: 6.064

Review 4.  Relationships between Efflux Pumps and Emergence of Heteroresistance: A Comprehensive Study on the Current Findings.

Authors:  Mohammad Abavisani; Mansoor Kodori; Fariba Akrami; Ali Radfar; Ali Hashemi
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-09-19       Impact factor: 2.585

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.